Tesamorelin + Ipamorelin blend

Tesamorelin + Ipamorelin is a two-peptide growth-hormone-secretagogue blend combining Tesamorelin and Ipamorelin in one vial, sold for research use only. It stands apart from the other GH blends for one reason: Tesamorelin is the only component across any of these blends that is actually FDA-approved — so the per-component lab data above matters as much for confirming which GHRH analog you have as for confirming how much.

What is the Tesamorelin + Ipamorelin blend?

Tesamorelin + Ipamorelin is a two-peptide blend pairing a growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone secretagogue, most commonly sold as 10 mg tesamorelin + 3 mg ipamorelin in a single vial (a fixed 10:3 ratio). Tesamorelin is a stabilised GHRH analog — the active ingredient in the FDA-approved drug Egrifta — that raises endogenous GH and IGF-1 output; Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that triggers a clean GH pulse without meaningfully raising cortisol or prolactin. The blend is oriented toward visceral-fat and body-recomposition research.

The two components, and what each contributes:

This pairing belongs to the growth-hormone-secretagogue family and is discussed alongside its comparators in Ipamorelin vs sermorelin vs tesamorelin.

Why are Tesamorelin and Ipamorelin combined?

Tesamorelin and Ipamorelin are combined because they raise growth hormone through two complementary mechanisms. Tesamorelin, as a GHRH analog, increases the amount of GH the pituitary produces and sustains higher IGF-1; Ipamorelin, as a selective ghrelin-receptor agonist, triggers a distinct GH pulse with minimal effect on cortisol or prolactin. Pairing a GHRH analog with a secretagogue produces a larger, more physiological pulse than either alone. The distinction from the more common CJC-1295 pairing is that Tesamorelin is a more potent, visceral-fat-targeted GHRH analog with actual regulatory approval behind it. Mechanism detail is in the Ipamorelin science guide and the Tesamorelin science guide.

What does the research show for Tesamorelin and Ipamorelin?

No controlled clinical trial of the Tesamorelin + Ipamorelin combination has been published as of August 2026 — but Tesamorelin carries the strongest human evidence of any ingredient in any of these blends. It is FDA-approved (Egrifta) for reducing excess visceral fat in HIV-associated lipodystrophy, on the strength of two double-blind placebo-controlled Phase 3 trials beginning with Falutz et al., NEJM 2007 and a pooled Phase 3 analysis, with visceral adipose tissue reductions of approximately 11–15% at 26 weeks (about six months) versus placebo in the pivotal HIV-lipodystrophy trials (evidence level: human RCT / FDA-approved, HIV-lipodystrophy population). Ipamorelin was characterised as the first selective GH secretagogue in preclinical and early human work (evidence level: preclinical and early clinical). Two honest limits: the visceral-fat data is for Tesamorelin monotherapy in a specific HIV population, not the blend and not the general public; and no trial has tested whether adding Ipamorelin improves on Tesamorelin alone.

How does Tesamorelin + Ipamorelin compare to CJC-1295 + Ipamorelin?

Both are GHRH-analog + Ipamorelin blends, so the real question is Tesamorelin versus CJC-1295 as the GHRH component. Tesamorelin is the more potent, visceral-fat-specific analog with FDA approval and RCT data; CJC-1295 (without DAC) is the cheaper, more common research analog with human pharmacodynamic data but no approval. Tesamorelin's evidence is stronger but comes from a narrow clinical population; CJC-1295 is the default in general GH-recomposition research. Neither combination has been tested as a blend in a controlled trial.

Why verify a Tesamorelin + Ipamorelin vial?

A Tesamorelin + Ipamorelin vial is worth verifying because two things can be wrong that a single number won't reveal: whether the GHRH component is really the (more expensive) tesamorelin, and whether each peptide is at label strength. A certificate reports one whole-vial HPLC purity — how clean the material is — but that can read above 99% while a component is underdosed or substituted, so the verifiable signals are per-component identity (mass spectrometry confirming both peptides by molecular weight) and net content (tested milligrams versus label, for each). Because tesamorelin is costlier than the cheaper GHRH analogs it can be swapped for, identity confirmation carries real weight here. Peptigrity's independent lab-test database publishes both dimensions; learn to read them in how to read peptide lab test results.

How does Peptigrity verify a Tesamorelin + Ipamorelin vial?

Peptigrity verifies a Tesamorelin + Ipamorelin vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming both peptides are present and are the peptides claimed, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for tesamorelin and ipamorelin individually), and endotoxin testing. Peptigrity collects independent third-party Certificates of Analysis for Tesamorelin + Ipamorelin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development; the methodology and shop trust-score weighting are documented in how we calculate trust scores. The broader process is in the how to test peptides hub and the testing labs directory. For sourcing the secretagogue component, see where to buy Ipamorelin.

How do you dose the Tesamorelin + Ipamorelin blend?

In a fixed 10:3 Tesamorelin + Ipamorelin vial you set the dose of one peptide and the other follows the ratio, since the two are present in a fixed proportion. A common research-planning approach reconstitutes the 13 mg vial (10 mg tesamorelin + 3 mg ipamorelin) and draws a single dose, often timed before sleep to align with the body's overnight GH pulse — the same nightly-timing logic used for tesamorelin monotherapy. The blend calculator converts the two amounts into a reconstitution and draw, and the tesamorelin calculator covers the tesamorelin component specifically. No clinical dosing protocol exists for the combination; The tesamorelin trial and original-approval dose (2 mg/day) is for HIV-associated lipodystrophy under medical supervision — the current EGRIFTA SV product doses 1.4 mg of the reformulation, not a self-administration guide for the blend.

What is the regulatory status of Tesamorelin and Ipamorelin?

The regulatory picture is split. Tesamorelin is FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-associated lipodystrophy — the only approved indication — but the research-grade tesamorelin sold in blends is not an approved product and is supplied for research use only. Ipamorelin is not approved for any indication. Ipamorelin acetate remains in Category 2 of the FDA's bulk-drug-substances evaluation (the 503B outsourcing-facility route) — it was not among the twelve peptides removed from Category 2 in April 2026 and is not on the Category 1 list eligible for compounding, as of August 2026. Both Tesamorelin (a GHRH analog) and Ipamorelin (a growth-hormone secretagogue) are prohibited at all times by the World Anti-Doping Agency under Section S2.2.4 (growth-hormone-releasing factors) of the Prohibited List, so the blend is banned in competitive sport. Buyers are responsible for confirming local import rules for research chemicals in their jurisdiction.